Findings:
Romanian patients have access to only 17% of new medicines approved in Europe (29 out of 167 from 2019-2022).
Wait times for access are much longer than the European average (778 days vs. 126 days in Germany).
Access varies by disease, with lower availability for oncology and orphan drugs (19%).
Key Takeaway:
Romanian patients face significant gaps in accessing innovative medicines due to delays, limited availability, and budgetary constraints.
Trend:
Limited access to new medicines seems to be persistent in Romania.
Conclusions:
Delays in the approval process and budgetary limitations are key hurdles.
Infrastructure and resource limitations hinder efficient treatment delivery.
Implications for Brands:
Pharmaceutical companies may face delays in launching new medicines in Romania.
Focus on therapies with high unmet medical need to justify potential challenges in market access.
Collaborate with policymakers to advocate for faster and more predictable approval processes.
Invest in initiatives that address infrastructure and resource limitations within the healthcare system.
Overall:
While the pharmaceutical industry can improve its efficiency, significant action from Romanian authorities is needed to improve patient access to innovative medicines.
Comments